http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이상엽 외 중앙대학교 의과대학 의학연구소 2004 中央醫大誌 Vol.29 No.1·2
The blood pressure (BP) response is a valuable predictor of coronary heart disease (CHD). However, little is known about the blood pressure responses, especially pulse pressure, mean arterial pressure during exercise. The purpose of this study was to evaluate the clinical significance of the blood pressure responses during exercise for prediciting CHD. The blood pressure responses during treadmill exercise test were measured in 82 patients who underwent coronary angiography. 58 patients had the coronary artery disease and 24 persons had normal coronary artery. The results were as follows: 1) During resting stage, the systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), mean arterial pressure (MAP) had no significant difference between patients with CHD and normal subjects (p>0.05). 2) During peak exercise, DBP (72 mmHg) in patients with CHD was significantly lower than in normal subjects (83 mmHg, p=0.004) and MAP (96 mmHg) in patients with CHD was significantly lower than in normal subjects (106 mmHg, p=0.02). SBP and PP were not significantly different between patients with CHD and normal subjects (p>0.05). 3) During recovery stage, the BP responses had no significant difference between patients with CHD and normal subjects (p>0.05). DBP during peak exercise was the most important factor of predicting CHD (p<0.0001). These results indicate that DBP and MAP during peak exercise was significantly lower in the patient with coronary artery disease. DBP and MAP during peak exercise seem to be a valuable predictor of the ischemic heart disease.
사이클링 선수의 슬관절각에 따른 하지동작의 운동학적 분석
류창엽,최성진,박종진,강순용 한국운동역학회 2001 한국운동역학회지 Vol.11 No.3
This study set out to evaluate the appropriateness of the height of a cycle saddle which was usually set based on a cyclist's experience and simple judgment. For this purpose, there was aroused a need to study what a cyclist's leg movements were according to the knee joint angle, that is, to study how a cyclist's leg joint angles and angular velocity would change at each pedaling. Seven male college cyclists were selected, and their pedaling movements were divided into four phases. The images were taped at 60fields/sec, using two video cameras. The KWON 3D 2.1 program was adopted to calculate and synchronize the 3D coordinates values which were calculated with DLT(Direct Liner Transformation), in order to analyze kinematical factors. The results were as follows: 1) There was found no difference between foot joint angles according to changes of knee joint angles in each phase. But it became clear that Phase 1 and 2 where the foot angle got bigger were the area where the foot joint was expanded and that Phase 3 and 4 where the foot angle got smaller were the area where the foot joint was bent. Accordingly, the area which gives a great indirect impact to the changes of foot joint angles is considered to be the first part of Phase 3 at which point the cycle of pedaling starts. 2) In terms of the difference of foot joint angular velocity according to knee joint angles, there was found a relatively stable deceleration in the decelerating area(Phase 3 and 4) while you could detect faster changes in the acceleration area(Phase 1 and 2) than in the decelerating area. 3) The changes in the angle difference of knee joints according to each knee joint angle showed almost similar patterns for every knee joint. But the patterns had the graph model of the opposite shape to that of the angle difference of foot joints. 4) The research went on to see what kind of difference the knee joint angle made as knee joint angular velocity changed. The changes were unlike the foot joint angular velocity and thus showed relatively slow deceleration and acceleration. And the higher the saddle was set, the bigger the difference of the angular velocity was. 5) The difference of hip joint angles according to knee joint angles made a graph pattern which showed no big correlation with the height of a saddle. 6) In considering how hip joint angular velocity would change according to knee joint angles, the higher a saddle was set, the bigger angular velocity was found in Phase 1 and 2, the area of joint expansion and the smaller angular velocity in Phase 3 and 4, the area of joint bending. Comparisons and analysis were made based on the results above mentioned. The conclusion was that the lower a saddle which was one of the three experiment conditions was set, the smoother the pedaling turned and the bigger the angular velocity was resulted. In other words, when you take a long road cycling with your saddle fixed at a little lower height than the average one, you will consume less physical strength and expect better performance.
Clinical Results of Drug-Coated Balloon Treatment in a Large-Scale Multicenter Korean Registry Study
Sang Yeub Lee,Yun-Kyeong Cho,Sang-Wook Kim,Young-Joon Hong,Bon-Kwon Koo,Jang-Whan Bae,Seung-Hwan Lee,Tae Hyun Yang,Hun Sik Park,Si Wan Choi,Do-Sun Lim,Soo-Joong Kim,Young Hoon Jeong,Hyun-Jong Lee,Kwan 대한심장학회 2022 Korean Circulation Journal Vol.52 No.6
Background and Objectives: The aim of this study was to demonstrate the efficacy and safety of treatment with drug-coated balloon (DCB) in a large real-world population. Methods: Patients treated with DCBs were included in a multicenter observational registry that enrolled patients from 18 hospitals in Korea between January 2009 and December 2017. The primary outcome was target lesion failure (TLF) defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically indicated target lesion revascularization at 12 months. Results: The study included 2,509 patients with 2,666 DCB-treated coronary artery lesions (1,688 [63.3%] with in-stent restenosis [ISR] lesions vs. 978 [36.7%] with de novo lesions). The mean age with standard deviation was 65.7±11.3 years; 65.7% of the patients were men. At 12 months, the primary outcome, TLF, occurred in 179 (6.7%), 151 (8.9%), 28 (2.9%) patients among the total, ISR, and de novo lesion populations, respectively. A history of hypertension, diabetes, acute coronary syndrome, previous coronary artery bypass graft, reduced left ventricular ejection fraction, B2C lesion and ISR lesion were independent predictors of 12 months TLF in the overall study population. Conclusions: This large multicenter DCB registry study revealed the favorable clinical outcome of DCB treatment in real-world practice in patient with ISR lesion as well as small de novo coronary lesion.
Sang Won Yoon,Myung Jae Park,이진국,Joo Hun Park,Sang Yeub Lee,Do Jin Kim,김도진,Jae Yeol Kim 대한내과학회 2020 The Korean Journal of Internal Medicine Vol.35 No.1
Background/Aims: There is insufficient quality data to recommend the use of herbs for the treatment of acute bronchitis. Small number of randomized trials of plant extracts for this purpose were determined to be low quality and there are concerns for the safety. HL301 is a combined product of seven medicinal plants. In the present study, we tried to evaluate the efficacy and safety of HL301 for the treatment of acute bronchitis with a randomized, double-blind, placebo-controlled, multicenter trial design. Methods: A total of 166 patients with acute bronchitis were randomized to receive placebo or HL301 (600 mg/day) for 7 days. The primary endpoint was change in bronchitis severity score (BSS) from baseline visit (visit 2) to the end of treatment (visit 3). Other efficacy variables were the change of each component of the BSS (cough, sputum, dyspnea, chest pain, and crackle) with treatment, response rate, improvement rate, satisfaction rate and number of rescue medications taken. Results: Changes in the BSS from visit 2 to visit 3 were higher in the HL301 group than in the placebo group both in the full analysis set (4.57 ± 1.82 vs. 3.15 ± 3.08, p < 0.01) and in the per protocol set (4.62 ± 1.81 vs. 3.30 ± 3.03, p < 0.01). Four BSS components (cough, sputum, dyspnea, and chest pain) improved more with HL301 treatment than with placebo treatment. Participants treated with HL301 showed higher response, improvement, and satisfaction rates and less use of rescue medication than the placebo group. Conclusions: HL301 (600 mg/day) was effective and safe for symptomatic treatment of acute bronchitis.